IMPORTANT SAFETY INFORMATION
WARNING: Life-threatening allergic reactions have occurred in some patients during VIMIZIM® (elosulfase alfa) infusions and up to 3 hours after infusion. Patients with acute respiratory illness may be at increased risk and require additional monitoring.

Learn how BioMarin RareConnections™ can help you start therapy with VIMIZIM

BioMarin RareConnections is focused on helping people with Morquio A get access to VIMIZIM therapy.

This program is available at no cost and provides confidential and personalized support to assist with your healthcare needs. The goal of BioMarin RareConnections™ is to help you navigate the healthcare system and get access to VIMIZIM® (elosulfase alfa) therapy as well as other resources to help you manage Morquio A. Just call
1-866-906-6100 or email support@biomarin-rareconnections.com to find out how BioMarin RareConnections can help you.

What does this really mean?

An Account Manager, Case Manager, and Clinical Nurse Educator all make up your experienced BioMarin RareConnections team, dedicated to helping you start and stay on VIMIZIM therapy.

Your BioMarin RareConnections Case Manager will help you coordinate all of the details of your treatment, including confirming that your insurance will pay for VIMIZIM. Most insurance plans will provide coverage for VIMIZIM, but if you need help getting insurance, your Case Manager will look for options to get you sufficient coverage. Your Case Manager will also put you in touch with other people at BioMarin who can help you work with your healthcare team and who can provide VIMIZIM and Morquio A education to you and your family.

Are you ready? Let’s talk.

Spanish-speaking case managers are also available.
También se dispone de coordinadores de casos de habla hispana.

To contact BioMarin RareConnections™, please fill out the online form
ac_bg
Ready to contact BioMarin RareConnections™ today? Please fill in your information and press the SUBMIT button.

* Required Fields

  • I have Morquio A.
    I am a caregiver for someone with Morquio A.
    I have a family member with Morquio A.
    I am a healthcare professional.
Benefiting from BioMarin RareConnections

In order to get started with BioMarin RareConnections, you’ll need to sign and return the Patient and Provider Authorization forms below. These forms help your healthcare team and BioMarin ensure that your insurance covers VIMIZIM, so you can start your treatment.

To start therapy with VIMIZIM

  • Read, sign, and return the forms to your doctor.
  • or

  • Read, sign, and follow the instructions printed on the forms to return them to BioMarin.
  • Once this step is completed, you will be enrolled in BioMarin RareConnections and your healthcare team and BioMarin can coordinate your VIMIZIM treatment.

    Indication

    VIMIZIM® (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

    Important Safety Information

    Life-threatening allergic reactions, known as anaphylaxis, can occur during VIMIZIM® (elosulfase alfa) infusions. Typical signs of anaphylaxis include cough, rash, throat tightness, hives, flushing, changes in skin color, low blood pressure, shortness of breath, chest pain, and gastrointestinal symptoms such as nausea, abdominal pain, retching, and vomiting. Contact your doctor or get medical help right away if these symptoms occur during or after VIMIZIM infusions. If you have a respiratory illness, you may be at risk for a sudden worsening of your condition, and you may require additional monitoring.

    VIMIZIM is a prescription medicine. Before treatment with VIMIZIM, it is important to discuss your medical history with your doctor. Tell your doctor if you are sick or taking any medication and if you are allergic to any medicines. Also tell your doctor if you are pregnant, planning to become pregnant, or are a nursing mother. Your doctor will decide if VIMIZIM is right for you. If you have questions or would like more information about VIMIZIM, contact your doctor.

    Anaphylaxis can occur during any VIMIZIM infusion and up to three hours after any infusion, and hypersensitivity reactions have been observed as early as 30 minutes from the start of infusion but as late as six days after infusion.

    Serious and severe reactions can happen with VIMIZIM treatment, including life-threatening allergic reactions (anaphylaxis), hives, swelling, cough, shortness of breath, and flushing. You should receive medication such as antihistamines before VIMIZIM infusions to reduce the risk of reactions. If a reaction occurs, the infusion should be slowed or stopped and you may be given additional medication. If a severe reaction occurs, the infusion should be stopped immediately and you will receive appropriate medical treatment.

    If you have acute febrile or respiratory illness at the time of VIMIZIM infusion you may be at higher risk of life-threatening complications from hypersensitivity reactions. If you use supplemental oxygen or continuous positive airway pressure (CPAP) you should have it available during your infusion in the event of a sudden reaction, or extreme drowsiness/sleep from antihistamines.

    Spinal cord damage may occur due to the natural MPS IVA disease process. Signs of spinal cord injury include back pain, numbness and paralysis, and loss of bladder and bowel control. Contact your doctor immediately if you develop any of these symptoms.

    The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. These are not all of the possible side effects with VIMIZIM. Talk to your doctor if you have any symptoms that bother you or that do not go away.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    For more information, call BioMarin RareConnections™ at 1-866-906-6100.

    CONTACT US

    BioMarin Pharmaceutical Inc.

    Novato, CA 94949

    BioMarin RareConnections™: 1-866-906-6100

    Biomarin